Alice B Gottlieb Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

4/2024	Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
2/2024	Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
2/2024	Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
2/2024	Atopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis.
12/2023	A Case Series of Patients With Eczematous Eruptions Following IL-17 Inhibitor Treatment for Psoriasis Vulgaris.
10/2023	A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies.
8/2023	Juvenile Pemphigus Foliaceus in a Patient With Psoriasis Receiving Narrow-Band Ultraviolet-B: Successful Treatment With Rituximab.
8/2023	Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program.
6/2023	Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
1/2023	Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alice B Gottlieb Research Topics

Disease

171	Psoriasis (Pustulosis Palmaris et Plantaris) 04/2024 - 05/2002
63	Psoriatic Arthritis 02/2024 - 09/2003
24	Infections 01/2022 - 11/2003
16	Neoplasms (Cancer) 01/2023 - 12/2005
9	Inflammation (Inflammations) 03/2024 - 12/2002
8	Necrosis 02/2024 - 02/2009
6	Atopic Dermatitis (Atopic Eczema) 02/2024 - 08/2005
6	Skin Diseases (Skin Disease) 10/2023 - 05/2003
6	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2021 - 01/2008
6	Pain (Aches) 01/2018 - 10/2010
5	Ankylosing Spondylitis 02/2024 - 01/2012
5	Arthritis (Polyarthritis) 01/2022 - 01/2006
5	Rheumatoid Arthritis 01/2016 - 01/2004
5	Skin Neoplasms (Skin Cancer) 07/2015 - 12/2008
4	Hidradenitis Suppurativa 12/2023 - 08/2016
3	Body Weight (Weight, Body) 05/2022 - 01/2008
3	Vitiligo 01/2022 - 06/2017
3	Tuberculosis (Tuberculoses) 12/2021 - 05/2007
3	Pruritus (Itching) 11/2020 - 04/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 12/2014 - 01/2008
3	Autoimmune Diseases (Autoimmune Disease) 04/2013 - 05/2007
2	Non-Radiographic Axial Spondyloarthritis 02/2024 - 04/2022
2	Axial Spondyloarthritis 02/2024 - 11/2023
2	Lichen Planus (Lichen Ruber Planus) 10/2023 - 07/2009
2	Headache (Headaches) 01/2023 - 03/2012
2	Injection Site Reaction 12/2021 - 01/2012
2	Hypertension (High Blood Pressure) 02/2021 - 08/2011
2	Hyperlipidemias (Hyperlipidemia) 02/2021 - 08/2011
2	Obesity 02/2021 - 08/2011
2	Acne Vulgaris 11/2020 - 03/2004
2	Pyoderma Gangrenosum 11/2016 - 11/2012
2	Dermatomyositis (Dermatopolymyositis) 11/2016 - 11/2008
2	Nasopharyngitis 10/2016 - 09/2015
2	Nail Diseases (Nail Disease) 12/2012 - 05/2007
2	Allergic Contact Dermatitis 03/2012 - 11/2006
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2012 - 11/2010
2	Tetanus 06/2010 - 11/2003

Drug/Important Bio-Agent (IBA)

30	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2024 - 12/2002
27	Etanercept (Enbrel)FDA Link 05/2022 - 11/2003
25	Monoclonal AntibodiesIBA 08/2023 - 11/2002
24	Ustekinumab (CNTO 1275)FDA Link 01/2021 - 06/2010
19	Tumor Necrosis Factor InhibitorsIBA 02/2024 - 11/2003
19	secukinumabIBA 02/2024 - 09/2013
19	Infliximab (Remicade)FDA Link 01/2021 - 01/2003
16	CytokinesIBA 03/2024 - 11/2002
12	Interleukin-17 (Interleukin 17)IBA 02/2024 - 11/2014
11	InterleukinsIBA 02/2024 - 06/2010
11	guselkumabIBA 10/2023 - 01/2018
10	bimekizumabIBA 04/2024 - 08/2018
10	Methotrexate (Mexate)FDA LinkGeneric 10/2023 - 01/2008
10	apremilastIBA 02/2021 - 03/2012
10	Adalimumab (Humira)FDA Link 01/2020 - 07/2006
10	efalizumab (Raptiva)FDA Link 07/2006 - 05/2002
9	Prostaglandins AIBA 01/2019 - 05/2003
9	Alefacept (Amevive)FDA Link 09/2011 - 11/2003
8	Interleukin-23 (Interleukin 23)IBA 11/2023 - 01/2012
8	Cyclosporine (Ciclosporin)FDA LinkGeneric 02/2020 - 08/2003
8	Interleukin-12 (IL 12)IBA 06/2014 - 12/2004
7	Biomarkers (Surrogate Marker)IBA 04/2024 - 07/2008
7	ixekizumabIBA 02/2024 - 09/2018
7	Immunoglobulin A (IgA)IBA 05/2022 - 03/2016
7	C-Reactive ProteinIBA 11/2020 - 08/2013
7	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2020 - 05/2003
5	Antirheumatic Agents (DMARD)IBA 11/2023 - 05/2014
5	tildrakizumabIBA 05/2022 - 01/2020
4	ruxolitinibIBA 03/2024 - 06/2017
4	Certolizumab Pegol FDA Link 06/2023 - 01/2018
4	Proteins (Proteins, Gene)FDA Link 10/2006 - 11/2002
3	ametantrone (HAQ)IBA 01/2023 - 06/2014
3	Tacrolimus (Prograf)FDA LinkGeneric 06/2020 - 08/2005
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 06/2020 - 09/2009
3	Hydroxyurea (Hydrea)FDA LinkGeneric 06/2020 - 11/2008
3	Leflunomide (Arava)FDA LinkGeneric 06/2020 - 09/2009
3	Acitretin FDA Link 02/2020 - 07/2007
3	omega-Chloroacetophenone (Mace)IBA 10/2017 - 12/2014
3	Immunoglobulins (Immunoglobulin)IBA 10/2010 - 04/2006
3	RetinoidsIBA 01/2008 - 07/2005
3	Immunoglobulin G (IgG)IBA 01/2006 - 11/2002
2	Janus Kinase InhibitorsIBA 10/2023 - 06/2017
2	Interleukin-23 Subunit p19IBA 02/2022 - 01/2020
2	FumaratesIBA 06/2020 - 09/2009
2	Thioguanine (Tioguanine)FDA Link 06/2020 - 09/2009
2	Abatacept (Orencia)FDA Link 09/2017 - 02/2015
2	InterferonsIBA 11/2016 - 12/2009
2	Messenger RNA (mRNA)IBA 08/2015 - 05/2007
2	golimumab FDA Link 07/2014 - 05/2010
2	Phosphodiesterase 4 InhibitorsIBA 04/2013 - 03/2012
2	tazarotene (Tazorac)FDA Link 09/2011 - 11/2002
2	Immunomodulating AgentsIBA 11/2010 - 08/2003
2	AntigensIBA 06/2010 - 09/2003

Therapy/Procedure

65	Therapeutics 02/2024 - 05/2003
12	Biological Therapy 05/2022 - 11/2002
10	Phototherapy (Light Therapy) 02/2020 - 12/2009
3	Immunomodulation 11/2010 - 04/2003
3	Immunotherapy 01/2004 - 01/2003
2	Complementary Therapies (Alternative Medicine) 10/2023 - 02/2021
2	Subcutaneous Injections 01/2020 - 01/2008
2	Excimer Lasers 09/2019 - 01/2012
2	Aftercare (After-Treatment) 10/2016 - 06/2008
2	Oral Administration 01/2012 - 10/2008